Business News • PR NewsWire • ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

LEUVEN, Belgium, May 24, 2017 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye...

View More : http://www.prnewswire.com/news-releases/thrombogenics-to-present-thr-317-pre-clinical-research-findings-at-the-european-...

Releted News by prnewswire

Nordic Nanovector ASA - Results for First Quarter 2017

XaitPorter is the Preferred Collaboration Tool Producing License Applications